BofA upgraded Apollo Medical to Buy from Neutral with a price target of $55, up from $44. The firm sees an inflection point in the growth story, with “high confidence” in the path to sustaining 30%-40%-plus revenue and 20%-plus EBITDA growth through at least 2026. As a result, it is raising its estimates above the Street, the analyst tells investors.
TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See Insiders’ Hot Stocks on TipRanks >>
Read More on AMEH: